COMORBID CONDITIONS

123. Is there a history of mechanical ventilation?  □ Yes  □ No
124. Is there a history of proven invasive fungal infection?  □ Yes  □ No

Were there clinically significant co-existing disease or organ impairment at time of patient assessment prior to preparative regimen?

□ Yes  □ No  □ Other

125. Other Specify: ____________________________

Other drug, specify: ______________________________________

159. Cyclosporine (CSA)
160. Campath
161. Other, specify: ____________________________

Box A  GVHD PROPHYLAXIS (ALLO ONLY)

145. Was GVHD prophylaxis planned/given?  □ Yes  □ No
(Change all that apply)

146. ALG, ALS, ATG, ATS (after d0)
147. Corticosteroids
148. Cyclosporine (CSA)
149. ECP (extra-corporeal photopheresis)
150. FK 506 (Tacrolimus, Prograf)
151. Methotrexate (MTX)
152. Cytoreductive chemotherapy
153. Anti CD25 (Zenapax, Daclizumab, AntiTAC)
154. Campath
155. Etanercept (Enbrel)
156. Infliximab (Remicade)
157. Other, specify: 158.

Box B  POST-HSCT DISEASE THERAPY PLANNED AS OF DAY 0

163. Is this HSCT part of a planned multiple (sequential) graft/HSCT protocol?  □ Yes  □ No
(Change all that apply) Optional for non-U.S. centers

164. Is additional post-HSCT therapy planned?  □ Yes  □ No
(Change all that apply)

165. Fluorodeoxyuridine (5-FU)
166. Interferon alpha

OTHER TOXICITY MODIFYING REGIMEN

Optional for non-U.S. Centers

170. Local radiotherapy
171. Rituximab (Rituxan, Mabthera)
172. Thalidomide (Thalomid)

* Abbreviations

YYY = 4 digit year
MM = 2 digit month
DD = 2 digit day
AHOP = Adult, Hematology, Oncology or Pediatric Unit
ALLO = Allogeneic
ANC = Absolute Neutrophil Count
AUTO = Autologous
BM = Bone Marrow
BMT-CTN = Blood & Marrow Transplant Clinical Trials Network
CIBMTR = Center for International Blood & Marrow Transplant Research
CIC = Center Identification Code
CMV = Cytomegalovirus
CR = Complete Remission
D = Disorders
DCI = Donor Cellular Infusion
DF = Differentiation or function
DLI = Donor Lymphocyte Infusion
DOB = Date of Birth
EBMT = European Group for Blood & Marrow Transplantation
EBV = Epstein Barr Virus
FACT = Foundation for the Accreditation of Cellular Therapy
FGF = Fibroblast Growth Factor
FISH = Fluorescent In-situ Hybridization
GVHD = Graft versus Host Disease
H SCT = Hematopoietic Stem Cell Transplant
IA = Inherited Abnormalities
IDOM = Inherited Disorders of Metabolism
KGF = Keratinocyte Growth Factor
MM = Minimum
MMR = Matched Related
MMU = Matched Unrelated
NMDP = National Marrow Donor Program
NRG = Not Related
OS = Other
PTLD = Posttransplant lymphoproliferative disorder
RBC = Red Blood Cell
RCI-BMT = Resource for Clinical Investigations in Blood & Marrow Transplant
RIC = Reduced Intensity Conditioning
SAA = Severe Aplastic Anemia
SCoT = Stem Cell Therapeutic Outcomes Database
TBI, TLI, TNI = Total (Body, Lymphoid, Nodal) Irradiation
T = Transplant
U = Unclassifiable
UCB = Umbilical Cord Blood
VOD = Veno-occlusive disease

Source: Blood, 2005 Oct 15;106(8):2912-2919
Select most specific W.H.O. classification:

- Acute Myelogenous Leukemia (AML) (10)
- AML with recurrent genetic abnormalities
  - AML with t(8;21)(q22;q22), (AML1/ETO) (281)
  - AML with abnormal BM eosinophils and inv(16)(p13q22) or t(16;16)(p13;q22), (CBFβ/MYH11) (282)
  - APL with t(15;17)(q22;q12), (PML/RARα) and variants/(M3) (283)
  - AML with t(1;1q23) (MLL) abnormalities (284)
  - AML with multilineage dysplasia (285)

- AML, not otherwise categorized/(NOS)
  - AML, minimally differentiated/(M0) (286)
  - AML without maturation/(M1) (287)
  - AML with maturation/(M2) (288)
  - Acute Myelomonocytic Leukemia/(M4) (289)
  - Acute Monoblastic/Acute Monocytic Leukemia/(M5) (290)
  - Acute Erythroid Leukemia (erythroid/myeloid and pure erythroleukemia)/(M6) (291)
  - Acute Megakaryoblastic Leukemia/(M7) (292)
  - Acute Basophilic Leukemia (293)
  - Acute Panmyelosis with Myelofibrosis (294)
  - Myeloid Sarcoma (295)
  - AML, NOS (280)

177. Did AML transform from MDS or MPS?

179. Was AML therapy related?

- AML therapy related (check all that apply)
  - Alkylating agent/radiation-related
  - Topoisomerase II inhibitor-related
  - Unknown

180. If known, indicate subtype:
- t(9;22)(q34;q11); BCR/ABL+ (192)
- t(v;11q23); MLL rearranged (193)
- t(1;19)(q23;p13) E2A/PBX1 (194)
- t(12;21)(p12;q22) ETV/CFB-α (195)

181. Did imatinib mesylate given for pretransplant therapy anytime prior to start of prep regimen?

Number
- 1st
- 2nd
- 3rd or higher

182. Status at Transplantation:
- Never treated
- Primary Induction Failure (PIF)
- Complete Remission (CR)
- Relapse
- For hematologic CR
  - Y
  - N
  - Unk

183. AML status on day 0:

Number
- AML 184, ALL 191, acLK 199
- AML 188, ALL 195, acLK 203
- 1st
- 2nd
- 3rd or higher

184. AML 184, ALL 191, acLK 199

185. AML 185, ALL 192, acLK 200

186. AML 186, ALL 193, acLK 201

187. AML 187, ALL 194, acLK 202
177. CHRONIC MYELOGENOUS LEUKEMIA (CML) (40)
Philadelphia chromosome+, Ph+, t(9;22)(q34;q11), or variant OR bcr/abl+

206. Did recipient receive treatment prior to this HSCT? [ ] Yes [ ] No
(check all that apply) Mandatory for CIBMTR comprehensive Report Form Teams:

207. Combination chemotherapy
208. Dasatinib (Sprycel)
209. Hydroxyurea (HU)
210. Imatinib mesylate (Gleevec, Glivec)
211. Interferon
212. Nilotinib (Tasigna)
213. Other, specify: ___________________________________________________

Status at Transplantation:

221. Number
[ ] 1st
[ ] 2nd
[ ] 3rd or higher

For Chronic Phase and CR Only:

217/219. Cytogenetic remission:
[ ] Complete
[ ] No
[ ] Cytogenetics unknown

218/220. Molecular remission (bcr/abl):
[ ] Yes
[ ] No
[ ] bcr/abl unknown

215. Phase
[ ] Hematologic CR

216. (Q.216 is not required for EBMT)
CML disease status before treatment that achieved this CR:
[ ] Chronic phase
[ ] Accelerated phase
[ ] Blast phase

177. MYELODYSPLASTIC OR MYELOPROLIFERATIVE DISEASES (50)

Classification:

WHO: Myelodysplastic Syndromes (MDS)

At diagnosis At transplantation
[ ] RA (51)
[ ] RARS (55)
[ ] RAEB-1 (61)
[ ] RAEB-2 (62)
[ ] RCMD (64)
[ ] RCMD/RS (65)
[ ] MDS Unclassifiable/ {NOS} (50)
[ ] AML
[ ] Isolated 5q-syndrome (66)
[ ] MDS, therapy related (check all that apply)
[ ] Alkylating agent/radiation-related
[ ] Topoisomerase II inhibitor-related
[ ] Unknown

224. Date of MDS Dx: ____________________ M M D D

Other

At diagnosis At transplantation
[ ] Chronic myelomonocytic leukemia (CMMoL, CMML) (54)
[ ] Juvenile myelomonocytic leukemia (JMM, JCML, JCMML) (36)

Was MDS/MPS therapy related? [ ] Yes [ ] No [ ] Unknown

JMML

Status at Transplantation:

234. [ ] CCR – Continued Complete Response
[ ] CR – Complete Response
[ ] PR – Partial Response
[ ] MR – Minimal Response
[ ] SD – Stable Disease
[ ] PD – Progressive Disease
[ ] Not assessed
### Pre-Transplant Essential Data

**Disease Classification Sheet**

**CIBMTR Center #:**

**CIBMTR Recipient ID #:**

#### OTHER LEUKEMIAS (30)

<table>
<thead>
<tr>
<th>Classification</th>
<th>Status at Transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>235. Atypical chronic myeloid leukemia (CML, NOS)</td>
<td>• Ph-/bcr/abl- (45)</td>
</tr>
<tr>
<td></td>
<td>• Ph-/bcr unknown (46)</td>
</tr>
<tr>
<td></td>
<td>• Ph unknown/bcr- (46)</td>
</tr>
<tr>
<td></td>
<td>• Ph unknown/bcr unknown (49)</td>
</tr>
<tr>
<td></td>
<td><strong>Never treated</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Complete Remission (CR)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>nodular Partial Remission (nPR)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Partial Remission (PR)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>No Response/Stable (NR/SD)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Progression</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Relapse (untreated)</strong></td>
</tr>
</tbody>
</table>

#### Chronic Lymphocytic Leukemia (CLL), NOS (34)

#### Chronic Lymphocytic Leukemia (CLL), B-cell/Small Lymphocytic Lymphoma (SLL) (71)

#### Hairy Cell Leukemia (35)

#### Prolymphocytic Leukemia (PLL), NOS (37)

#### Other leukemia (39), specify:____________________

#### Other leukemia, NOS (30)

#### LYMPHOMAS

**Classification:**

<table>
<thead>
<tr>
<th>Classification</th>
<th>Status at Transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>177. □ Hodgkin Lymphoma (150)</td>
<td><strong>Grade I</strong> (102)</td>
</tr>
<tr>
<td></td>
<td><strong>Grade II</strong> (103)</td>
</tr>
<tr>
<td></td>
<td><strong>Grade III</strong> (104)</td>
</tr>
<tr>
<td></td>
<td><strong>Unknown</strong> (164)</td>
</tr>
<tr>
<td>238. □ Nodular lymphocyte predominant Hodgkin lymphoma (155)</td>
<td><strong>Never treated</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Primary refractory (less than PR to initial therapy)/PIF res</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Partial response (PR)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Complete response (CR)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>CR confirmed</strong></td>
</tr>
<tr>
<td></td>
<td><strong>CR unconfirmed (CRU)</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Relapse (untreated)</strong></td>
</tr>
</tbody>
</table>

**Status at Transplantation:**

* CRU – complete response with persistent scan abnormalities of unknown significance

#### Hodgkin Lymphoma (150)

- Burkitt’s lymphoma/Burkitt cell leukemia (ALL L3) (111)
- High-grade B-cell lymphoma, Burkitt-like (provisional entity) (135)
- Diffuse large B-cell lymphoma (107)
- If known, indicate subtype:
  - Intravascular large B-cell lymphoma (136)
  - Mediastinal large B-cell lymphoma (125)
  - Primary effusion lymphoma (136)
  - Extramedullary marginal zone B-cell lymphoma of MALT type (122)
  - Follicular lymphoma (includes variants) (121)
  - Mantle cell lymphoma (115)
  - Nodal marginal zone B-cell lymphoma (+/- monocytoid B cells) (123)
  - Primary CNS lymphoma (118)
  - Splenic marginal zone B-cell lymphoma (124)
  - Waldenstrom macroglobulinemia (173)
  - Other B-cell lymphoma (129),
  - Other:____________________

#### Non-Hodgkin’s Lymphoma (150) (continued)

- Adult T-cell lymphoma/leukemia (HTLV1+) (134)
- Aggressive NK-cell leukemia (27)
- Anaplastic large-cell lymphoma, T/null cell, primary cutaneous type (147)
- Anaplastic large-cell lymphoma, T/null cell, primary systemic type (148)
- Angioimmunoblastic T-cell lymphoma (AILD) (131)
- Enteropathy-type T-cell lymphoma (133)
- Extranodal NK/T-cell lymphoma, nasal type (137)
- Hepatosplenic gamma-delta T-cell lymphoma (145)
- Mycosis fungoides (141)
- Peripheral T-cell lymphoma (NOS) (130)
- Subcutaneous panniculitis-like T-cell lymphoma (146)
- Sézary syndrome (142)
- Large T-cell granular lymphocytic leukemia (126)
- Other T/NK cell lymphoma (139),
- Other:____________________

#### T-cell and NK-cell Neoplasms

#### Sensitivity to Chemotherapy

- Sensitive
- Resistant
- Untreated
- Unknown

**Pre-TED (8/04/09) Page 5 of 10**
### PLASMA CELL DISORDERS (170)

#### Classification:
- Multiple myeloma-lgG (181)
- Multiple myeloma-lgA (182)
- Multiple myeloma-lgD (183)
- Multiple myeloma-lgE (184)
- Multiple myeloma-lgM (not Waldenstrom macroglobulinemia) (185)
- Multiple myeloma-light chain only (186)
- Multiple myeloma-non-secretory (187)
- Plasma cell leukemia (172)
- Solitary plasmacytoma (no evidence of myeloma) (175)
- Primary Amyloidosis (174)
- Other Plasma Cell Disorder (179), specify: ______________________

#### Status at Transplantation:
- Never treated
- Complete Remission (CR)
- Stringent Complete Remission (sCR)
- Very Good Partial Response (VGPR)
- Partial Response (PR)
- Stable Disease (SD)
- Progression
- Relapse from CR (untreated)

### BREAST CANCER (250)

#### Classification:
- Inflammatory (251)
- Non-inflammatory (252)

#### Status at Transplantation:
- Adjuvant (Stage II, III only)
- Never treated
- Primary refractory
- Complete remission (CR)
- CR confirmed
- CR unconfirmed (CRU)
- 1st partial response (PR1)
- Relapse

### “OTHER” DISEASE (900)

Specify [900]: 272

Before using this category, check with transplant physician whether diagnosis can be classified among options on Disease Classification Pages 3-10.

For any “other” disease: Is a pathology report attached to this form?
- Yes
- No

---

**Pre-Transplant Essential Data Disease Classification Sheet**

CIBMTR Recipient ID #: [Redacted]

CIBMTR Center #: [Redacted]

**Classification:**
- Light Chain
  - Kappa
  - Lambda
  - I.S.S.: Serum β₂-microglobulin:
    - 1 µg/dL
    - 2 mg/L
    - 3 nmol/L

**Status at Transplantation:**
- Never treated
- Complete Remission (CR)
- Stringent Complete Remission (sCR)
- Very Good Partial Response (VGPR)
- Partial Response (PR)
- Stable Disease (SD)
- Progression
- Relapse from CR (untreated)

**Sensitivity to Chemotherapy:**
- Sensitive
- Resistant
- Untreated
- Unknown

**Alternative HCT:**
- Cardiac regeneration
- Neurologic regeneration
- Tolerance Induction Pre-solid Organ Transplant
- Other, specify: 275
276. **Classification:**

- Bone sarcoma (excluding Ewing family tumors) (273)
- Central nervous system tumors (include CNS PNET) (220)
- Colorectal (228)
- Ewing family tumors extra-osseous (includes PNET) (276)
- Ewing family tumors of bone (includes PNET) (275)
- Germ cell tumor, extragonadal only (225)
- Hepatobiliary (207)
- Lung cancer, non-small cell (203)
- Lung cancer, small cell (202)
- Medulloblastoma (226)
- Melanoma (219)
- Neuroblastoma (222)
- Ovary (214)
- Pancreas (206)
- Prostate (209)
- Renal cell (208)
- Retinoblastoma (223)
- Rhabdomyosarcoma (232)
- Soft tissue sarcoma (274)
- Testicular (210)
- Thymoma (231)
- Wilm tumor (221)
- Other solid tumor (269), specify: __________

278. **Status at Transplantation:**

- Adjuvant
- Never treated
- CR
- CRU
- PR
- NR/SD
- PD
- Relapse (untreated)

281. **Number**

(complete for CR, CRU or relapse)

- 1st
- 2nd
- 3rd or higher

282. **Sensitivity to Chemotherapy**

(complete only for relapse)

- Sensitive (PR)
- Resistant (SD, PD)
- Untreated
- Unknown

283. **Severe aplastic anemia**

- Acquired Severe Aplastic Anemia (SAA), NOS (301)
- Acquired SAA, secondary to hepatitis (302)
- Acquired SAA, secondary to toxin/other drug (303)
- Acquired Amegakaryocytosis (not congenital) (304)
- Acquired Pure Red Cell Aplasia (PRCA) (not congenital) (306)
- Other acquired cytopenic syndrome (309), specify:
- Paroxysmal nocturnal hemoglobinuria (PNH) (56)

284. **ANEMIA** (300)

- Acquired Severe Aplastic Anemia (SAA), NOS (301)
- Acquired SAA, secondary to hepatitis (302)
- Acquired SAA, secondary to toxin/other drug (303)
- Acquired Amegakaryocytosis (not congenital) (304)
- Acquired Pure Red Cell Aplasia (PRCA) (not congenital) (306)
- Other acquired cytopenic syndrome (309), specify:
- Paroxysmal nocturnal hemoglobinuria (PNH) (56)

285. **HEMOGLOBINOPATHY** (310)

- Fanconi anemia (311)
- Diamond-Blackfan anemia (congenital PRCA) (312)
- Shwachman-Diamond (305)
- Other constitutional anemia (319), specify:
- Sickle cell disease (356)
- Sickle thalassemia (355)
- Thalassemia NOS (350)
- Other hemoglobinopathy (359), specify:

286. **PLATELET DISORDERS** (500)

- Congenital amegakaryocytosis/congenital thrombocytopenia (501)
- Glanzmann thrombasthenia (502)
- Other inherited platelet abnormalities (509), specify: 289.

287. **HISTIOCYTIC DISORDERS** (570)

- Histiocytic disorders, NOS (570)
- Familial erythro/hemohagocytic lymphohistiocytosis (FELH) (571)
- Langerhans Cell Histiocytosis (Histiocytosis-X) (572)
- Hemophagocytosis (reactive or viral associated) (573)
- Malignant histiocytosis (574)
- Other histiocytic disorder (579), specify: 291.
### 177. Inherited Disorders of Metabolism/Osteopetrosis (520)

<table>
<thead>
<tr>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adrenoleukodystrophy (ALD) (543)</td>
</tr>
<tr>
<td>Aspartyl glucosaminuria (561)</td>
</tr>
<tr>
<td>B-glucuronidase deficiency (VII) (537)</td>
</tr>
<tr>
<td>Fucosidosis (562)</td>
</tr>
<tr>
<td>Gaucher disease (541)</td>
</tr>
<tr>
<td>Glucose storage disease (548)</td>
</tr>
<tr>
<td>Hunter syndrome (II) (533)</td>
</tr>
<tr>
<td>Hurler syndrome (IH) (531)</td>
</tr>
<tr>
<td>I-cell disease (546)</td>
</tr>
<tr>
<td>Krabbe disease (globoid leukodystrophy) (544)</td>
</tr>
<tr>
<td>Lesch-Nyhan (HGPRT deficiency) (522)</td>
</tr>
<tr>
<td>Mannosidosis (563)</td>
</tr>
<tr>
<td>Maroteaux-Lamy (VI) (536)</td>
</tr>
<tr>
<td>Metachromatic leukodystrophy (MLD) (542)</td>
</tr>
<tr>
<td>Morquio (IV) (535)</td>
</tr>
<tr>
<td>Mucolipidoses, NOS (540)</td>
</tr>
<tr>
<td>Mucopolysaccharidosis (V) (538)</td>
</tr>
<tr>
<td>Mucopolysaccharidosis, NOS (530)</td>
</tr>
<tr>
<td>Neimann-Pick disease (545)</td>
</tr>
<tr>
<td>Neuronal ceroid – lipofuscinosis (Batten disease) (523)</td>
</tr>
<tr>
<td>Osteopetrosis (malignant infantile osteopetrosis) (521)</td>
</tr>
<tr>
<td>Sanfilippo (III) (534)</td>
</tr>
<tr>
<td>Scheie syndrome (IS) (532)</td>
</tr>
<tr>
<td>Wolman disease (547)</td>
</tr>
</tbody>
</table>
| Other inherited disorder of metabolism (529), Spec:

### 177. Immune Deficiencies (400)

<table>
<thead>
<tr>
<th>Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ataxia telangiectasia (451)</td>
</tr>
<tr>
<td>Bare lymphocyte syndrome (406)</td>
</tr>
<tr>
<td>DiGeorge anomaly (454)</td>
</tr>
<tr>
<td>CD 40 Ligand deficiency (464)</td>
</tr>
<tr>
<td>Cartilage hair hypoplasia (462)</td>
</tr>
<tr>
<td>Chediak-Higashi syndrome (456)</td>
</tr>
<tr>
<td>Chronic granulomatous disease (455)</td>
</tr>
<tr>
<td>Common variable immunodeficiency (457)</td>
</tr>
<tr>
<td>HIV infection (452)</td>
</tr>
<tr>
<td>Immune Deficiencies, NOS (400)</td>
</tr>
<tr>
<td>Leukocyte adhesion deficiencies (459)</td>
</tr>
<tr>
<td>Kostmann syndrome-congenital neutropenia (460)</td>
</tr>
<tr>
<td>Neutrophil actin deficiency (461)</td>
</tr>
<tr>
<td>Omenn syndrome (404)</td>
</tr>
<tr>
<td>Reticular dysgenesis (405)</td>
</tr>
<tr>
<td>SCID, ADA deficiency severe combined immune deficiency (401)</td>
</tr>
<tr>
<td>SCID, Absence of T and B cells (402)</td>
</tr>
<tr>
<td>SCID, Absence of T, normal B cell (403)</td>
</tr>
<tr>
<td>SCID, NOS (410)</td>
</tr>
</tbody>
</table>
| SCID other (419), Spec:

Wiskott Aldrich syndrome (453)

X-linked lymphoproliferative syndrome (458)

Other immune deficiency (479), Spec:

---

292. Classification:

293. Spec:

296. Spec:
### 177. AUTOIMMUNE DISORDERS (600)

#### Connective Tissue Disease

<table>
<thead>
<tr>
<th>Classification</th>
<th>Involved Organs/Clinical Problem(s)</th>
<th>Primary Reason(s) for Transplant</th>
<th>Miscellaneous Labs</th>
</tr>
</thead>
<tbody>
<tr>
<td>297. Systemic sclerosis (607)</td>
<td>diffuse cutaneous</td>
<td>Yes</td>
<td>Antibodies: normal elevated not done</td>
</tr>
<tr>
<td>297.</td>
<td>limited cutaneous</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>297.</td>
<td>lung parenchyma</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>297.</td>
<td>pulmonary hypertension</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>297.</td>
<td>systemic hypertension</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>308.</td>
<td>renal (biopsy type: 310.)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>311.</td>
<td>esophagus</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>313.</td>
<td>other GI Tract</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>315.</td>
<td>Raynaud</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>317.</td>
<td>CREST</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>319.</td>
<td>other, specify: 321</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

#### Systemic lupus erythematosus (SLE) (605)

<table>
<thead>
<tr>
<th>Classification</th>
<th>Involved Organs/Clinical Problem(s)</th>
<th>Primary Reason(s) for Transplant</th>
<th>Miscellaneous Labs</th>
</tr>
</thead>
<tbody>
<tr>
<td>327.</td>
<td>renal (biopsy type: 327.)</td>
<td>Yes</td>
<td>Antibodies: normal elevated not done</td>
</tr>
<tr>
<td>328.</td>
<td>CNS (type: 330.)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>331.</td>
<td>PNS (type: 333.)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>334.</td>
<td>lung</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>336.</td>
<td>serositis</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>338.</td>
<td>arthritis</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>340.</td>
<td>skin (type: 342.)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>343.</td>
<td>hematological (type: 345.)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>346.</td>
<td>vasculitis (type: 348.)</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

#### Sjögren syndrome (608)

<table>
<thead>
<tr>
<th>Classification</th>
<th>Involved Organs/Clinical Problem(s)</th>
<th>Primary Reason(s) for Transplant</th>
<th>Miscellaneous Labs</th>
</tr>
</thead>
<tbody>
<tr>
<td>359.</td>
<td>SICCA</td>
<td>Yes</td>
<td>Antibodies: normal elevated not done</td>
</tr>
<tr>
<td>361.</td>
<td>exocrine gland swelling</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>363.</td>
<td>other organ lymphocytic infiltration</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>365.</td>
<td>lymphoma, paraproteinemia</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>367.</td>
<td>vasculitis</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>369.</td>
<td>other, specify: 371</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

#### Polymyositis-dermatomyositis (606)

<table>
<thead>
<tr>
<th>Classification</th>
<th>Involved Organs/Clinical Problem(s)</th>
<th>Primary Reason(s) for Transplant</th>
<th>Miscellaneous Labs</th>
</tr>
</thead>
<tbody>
<tr>
<td>372.</td>
<td>proximal weakness</td>
<td>Yes</td>
<td>Antibodies: normal elevated not done</td>
</tr>
<tr>
<td>374.</td>
<td>generalized weakness (including bulbar)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>376.</td>
<td>pulmonary fibrosis</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>378.</td>
<td>vasculitis (type: 380)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>381.</td>
<td>malignancy (type: 383)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>384.</td>
<td>other, specify: 386</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

#### Antiphospholipid syndrome (603)

<table>
<thead>
<tr>
<th>Classification</th>
<th>Involved Organs/Clinical Problem(s)</th>
<th>Primary Reason(s) for Transplant</th>
<th>Miscellaneous Labs</th>
</tr>
</thead>
<tbody>
<tr>
<td>391.</td>
<td>thrombosis (type: 393)</td>
<td>Yes</td>
<td>Antibodies: normal elevated not done</td>
</tr>
<tr>
<td>394.</td>
<td>CNS (type: 396)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>397.</td>
<td>abortion</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>399.</td>
<td>skin (livedo, vasculitis)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>401.</td>
<td>hematological (type: 403)</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

#### Other connective tissue disease, specify (634); 410.

### Vasculitis

<table>
<thead>
<tr>
<th>Classification</th>
<th>Involved Organs/Clinical Problem(s)</th>
<th>Primary Reason(s) for Transplant</th>
<th>Miscellaneous Labs</th>
</tr>
</thead>
<tbody>
<tr>
<td>411.</td>
<td>upper respiratory tract</td>
<td>Yes</td>
<td>Antibodies: normal elevated not done</td>
</tr>
<tr>
<td>413.</td>
<td>pulmonary</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>415.</td>
<td>renal (biopsy type: 417)</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>418.</td>
<td>skin</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>420.</td>
<td>other, specify: 422</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

#### Wegener granulomatosis (610)

<table>
<thead>
<tr>
<th>Classification</th>
<th>Involved Organs/Clinical Problem(s)</th>
<th>Primary Reason(s) for Transplant</th>
<th>Miscellaneous Labs</th>
</tr>
</thead>
<tbody>
<tr>
<td>428.</td>
<td>renal (type: 430)</td>
<td>Yes</td>
<td>Antibodies: normal elevated not done</td>
</tr>
</tbody>
</table>

#### Polyarteritis nodosa

<table>
<thead>
<tr>
<th>Classification</th>
<th>Involved Organs/Clinical Problem(s)</th>
<th>Primary Reason(s) for Transplant</th>
<th>Miscellaneous Labs</th>
</tr>
</thead>
<tbody>
<tr>
<td>429.</td>
<td>urinary:________________</td>
<td>Yes</td>
<td>Antibodies: normal elevated not done</td>
</tr>
<tr>
<td>431.</td>
<td>mononeuritis multiplex</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>433.</td>
<td>pulmonary hemorrhage</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>435.</td>
<td>skin</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>437.</td>
<td>GI Tract</td>
<td>No</td>
<td></td>
</tr>
<tr>
<td>439.</td>
<td>other, specify: 441</td>
<td>No</td>
<td></td>
</tr>
</tbody>
</table>

#### SLE (605)

<table>
<thead>
<tr>
<th>Classification</th>
<th>Involved Organs/Clinical Problem(s)</th>
<th>Primary Reason(s) for Transplant</th>
<th>Miscellaneous Labs</th>
</tr>
</thead>
<tbody>
<tr>
<td>435.</td>
<td>renal</td>
<td>Yes</td>
<td>Antibodies: normal elevated not done</td>
</tr>
</tbody>
</table>

### NOTE: Transplant Essential Data should be submitted at time of mobilization for all patients with autoimmune disease
### Autoimmune Disorders

#### Classification
- Choose the classification that best describes the involved organs/clinical problem(s).

#### Involved Organs/Clinical Problem(s)
- Please specify all applicable issues.

#### Primary Reason(s) for Transplant
- Check all that apply.

#### Miscellaneous Labs
- Check all that apply.

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arthritis</td>
<td>Rheumatoid arthritis (603)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>destructive arthritis</td>
<td>446</td>
<td></td>
</tr>
<tr>
<td></td>
<td>necrotizing vasculitis</td>
<td>448</td>
<td></td>
</tr>
<tr>
<td></td>
<td>eye (type: 452)</td>
<td>450</td>
<td></td>
</tr>
<tr>
<td></td>
<td>pulmonary</td>
<td>453</td>
<td></td>
</tr>
<tr>
<td></td>
<td>extra-articular (specify: 457)</td>
<td>455</td>
<td></td>
</tr>
<tr>
<td></td>
<td>other, specify: 460</td>
<td>458</td>
<td></td>
</tr>
<tr>
<td>Psoriatic arthritis/psoriasis (604)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>destructive arthritis</td>
<td>461</td>
<td></td>
</tr>
<tr>
<td></td>
<td>psoriasis</td>
<td>463</td>
<td></td>
</tr>
<tr>
<td></td>
<td>other, specify: 467</td>
<td>465</td>
<td></td>
</tr>
<tr>
<td>Juvenile idiopathic arthritis: systemic (Still's disease) (640)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>primary progressive</td>
<td>470</td>
<td></td>
</tr>
<tr>
<td></td>
<td>secondary progressive</td>
<td>472</td>
<td></td>
</tr>
<tr>
<td></td>
<td>relapsing/remitting</td>
<td>474</td>
<td></td>
</tr>
<tr>
<td></td>
<td>other specify: 476</td>
<td>476</td>
<td></td>
</tr>
<tr>
<td>Multiple sclerosis (MS) (602)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>primary progressive</td>
<td>470</td>
<td></td>
</tr>
<tr>
<td></td>
<td>secondary progressive</td>
<td>472</td>
<td></td>
</tr>
<tr>
<td></td>
<td>relapsing/remitting</td>
<td>474</td>
<td></td>
</tr>
<tr>
<td></td>
<td>other specify: 476</td>
<td>476</td>
<td></td>
</tr>
<tr>
<td>Myasthenia gravis (601)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other autoimmune neurological disorder, specify (644)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>hematological autoimmune disease disorder, specify (644)</td>
<td>479</td>
<td></td>
</tr>
<tr>
<td></td>
<td>idiopathic thrombocytopenic purpura (ITP) (645)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Hemolytic anemia (646)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Evan syndrome (647)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>other autoimmune cytopenia, specify (648)</td>
<td>480</td>
<td></td>
</tr>
<tr>
<td>Crohn's disease (649)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ulcerative colitis (650)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>other autoimmune bowel disorder, specify (651)</td>
<td>481</td>
<td></td>
</tr>
</tbody>
</table>